✦ LIBER ✦

Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial

✍ Scribed by Hitoshi Takashi; Takio Sugita; Hisashi Higuchi; Tetsuo Shimizu

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 51 KB
Volume: 17
Category: Article
ISSN: 0885-6222
DOI: 10.1002/hup.367

No coin nor oath required. For personal study only.

✦ Synopsis

We investigated the efficacy and safety of augmenting risperidone with fluvoxamine for the treatment of residual positive and negative symptoms in patients with chronic schizophrenia who had shown an incomplete response to risperidone. A total of 30 patients completed the open trial over a 12-week period during which fluvoxamine was added to risperidone. The result from the positive and negative syndrome scale (PANSS) and Simpson-Angus extrapyramidal effects (S-A) scale were examined at baseline, 1, 2, 4, 8 and 12 weeks of treatment. There were no significant differences in PANSS positive, negative and general psychopathology scores, or in S-A scale scores at any point during the treatment. These results suggest that fluvoxamine appears to be ineffective in augmenting the risperidone treatment response in chronic schizophrenic patients. Further controlled trials will be needed to confirm this observation.

📜 SIMILAR VOLUMES

Fluvoxamine augmentation in chronic schi

Fluvoxamine augmentation in chronic schizophrenia: An open exploratory study

✍ Henry Silver; Alla Kaplan; Mina Kushnir 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB

The effect of augmenting standard antipsychotic treatment with the specific serotonergic reuptake inhibitor (SSRI) fluvoxamine was examined in severely disabled chronic schizophrenic inpatients using an open, naturalistic protocol. Fluvoxamine in doses ranging from 25 to 200 mg was added to the ant

Amisulpiride augmentation in treatment r

Amisulpiride augmentation in treatment resistant obsessive–compulsive disorder: an open trial

✍ Özmen Metin; Kemal Yazici; Senel Tot; Aylin Ertekin Yazici 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB 👁 1 views

## Abstract Despite the effectiveness of clomipramine and selective serotonin reuptake inhibitors (SSRIs) in the treatment of obsessive–compulsive disorder (OCD), 40% to 60% of patients who receive an adequate treatment with these agents have significant persisting symptoms. Newer atypical antipsyc

Thyroxine Augmentation of Fluoxetine Tre

Thyroxine Augmentation of Fluoxetine Treatment for Resistant Depression in the Elderly: An Open Trial

✍ YORAM BARAK; DANIEL STEIN; JOSEPH LEVINE; ALIZA RING; JACK HADJEZ; AVNER ELIZUR; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB 👁 2 views

Drug resistant depression is a confounding entity. More so in populations of elderly depressives where addition of lithium or antidepressant combinations are possibly hazardous. We present an open-trial of thyroxine in elderly patients diagnosed as suffering from resistant depression. Methods -Thyro

An open study of risperidone liquid in t

An open study of risperidone liquid in the acute phase of schizophrenia

✍ Reiji Yoshimura; Jun Nakamura; Koji Shinkai; Makiko Goto; Yasuhisa Yamada; Kyoko 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

## Abstract An open‐label study was performed to investigate the clinical efficacy and mechanisms of risperidone liquid in ameliorating positive symptoms in the acute phase of schizophrenia. Eighty‐eight patients (M/F: 50/38; age: 18–74 years;, mean±SD =32±16 years) meeting DSM‐IV criteria for schi

The sequential treatment approach to res

The sequential treatment approach to resistant schizophrenia with risperidone and clozapine: results of an open study with follow-up

✍ R. Cavallaro; P. Brambilla; E. Smeraldi 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 2 views

In this paper we extend and test with long-term follow-up the results of a previous paper on the usefulness of a sequential treatment protocol with risperidone and clozapine in resistant schizophrenia. Twenty-four patients diagnosed as resistant schizophrenics according to DSM III R and Kane et al.

Risperidone in the treatment of dopamine

Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial

✍ Erich Mohr; Tilak Mendis; Kathleen Hildebrand; Peter Paul De Deyn 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 2 views

## Purpose: To evaluate the safety and efficacy of risperidone in patients with parkinson's disease (pd) who are experiencing significant dopamine-induced psychosis. ## Patients and methods: Seventeen patients (median age, 72 yrs) participated in this 12-week, open pilot study receiving 0.5 to 3